The announcements about the vaccines and their potential availability for use among the general population in the coming weeks and months has offered hope to millions around the world in a year that has seen the COVID-19 pandemic devastate lives and economies and still showing no signs of abating.Moderna also plans to submit applications for authorisations to global regulatory agencies.While the two vaccines appear to have very similar safety and efficacy profiles, Moderna&Plastic Injection Molding Machine39;s vaccine has a significant practical advantage over Pfizer's, CNN reported.. We remain committed to and focused on doing our part to help end the COVID-19 pandemic. Another advantage of Moderna's vaccine is that it can be kept for 30 days in the refrigerator, the company announced on Monday.5 per cent," Moderna said in a statement.

So far the coronavirus has infected more than 54 million people around the world even as governments implemented strict lockdowns and restrictions to slow the spread of the virus that originated in the Chinese city of Wuhan.5 per cent effective in preventing the deadly disease, bringing a glimmer of hope to a world ravaged by the pandemic.Based on these interim safety and efficacy data, Moderna intends to submit for an Emergency Use Authorisation (EUA) with the US Food and Drug Administration (USFDA) in the coming weeks and anticipates having the EUA informed by the final safety and efficacy data.This study, known as the COVE study, enrolled more than 30,000 participants in the US, it added. Both require people to get two shots, several weeks apart.Vaccinations could begin in the second half of December, Fauci said.3 million people worldwide, more than 245,000 of them in the US.

The Sputnik V vaccine, developed in Russia, has also released very early data which suggests it is 92 per cent effective. All along, we have known that each day matters," said Stephane Bancel, CEO of Moderna."We leverage infrastructure that already exists for other marketed vaccines.“This first interim analysis was based on 95 cases, of which 90 cases of COVID-19 were observed in the placebo group versus 5 cases observed in the mRNA-1273 group, resulting in a point estimate of vaccine efficacy of 94. This positive interim analysis from our Phase 3 study has given us the first clinical validation that our vaccine can prevent COVID-19 disease, including severe disease,” Bancel said as the pandemic has killed more than 1.A review of solicited adverse effects indicated that the vaccine was generally well tolerated.